GNLX · Genelux Corp
United States · RS rating 16 · As of 2026-11-03
| Price | 1.92 USD |
|---|---|
| 1-day change | -4.0% |
| RS rating (overall / 1M / 3M / 12M) | 16 / 15 / 27 / 10 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 19 / 4 / 14 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -5.0% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +76.7% |
| Market cap (USD) | $112.9M |